A previous clinical trial found that tamoxifen, taken for five years, reduced the risk of developing invasive breast cancer by about 50% in post-menopausal women who were at increased risk of getting the disease.
Another trial found that five years of raloxifene reduces breast cancer risk in such women by about 38%.
Under the new plans, high risk post-menopausal women could be offered the drugs for a period of five years unless they have a history of thromboembolic disease or endometrial cancer.
More top news
Paracetamol is ineffective at treating back pain, Australian researchers say.
Madonna says she still cannot bring herself to watch footage of the moment she fell on stage while performing at the Brit Awards.
Ed Miliband has pledged to give zero-hours workers the right to convert their contract into a regular job after three months.